Trial Profile

Phase II trial of eribulin in patients with recurrent glioblastoma (ENIGMA)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eribulin (Primary)
Indications Glioblastoma; Gliosarcoma
Focus Therapeutic Use
Acronyms ENIGMA

Most Recent Events

07 Jun 2022 Primary endpoint (One-year survival rate) has been met, according to Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
08 Oct 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com